OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference Jul 26, 2021 8:30am EDT
OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma Jul 06, 2021 4:01pm EDT
OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering Jun 14, 2021 8:30am EDT
OncoSec Appoints Robert M. Schinagl, Ph.D. as Vice President of Program and Alliance Management May 17, 2021 8:30am EDT
OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma Apr 15, 2021 8:30am EDT
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse™" for the Treatment of Solid Tumors Apr 14, 2021 8:30am EDT
OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma Mar 25, 2021 8:39am EDT
